The Complexities of Resistance to Bevacizumab - Journal of Cancer Therapy

JCT > Vol.3 No.5, October 2012

The Complexities of Resistance to Bevacizumab ()

HTML

Download as PDF (Size: 227KB) PP. 491-503

DOI: 10.4236/jct.2012.35064 4,585 Downloads 8,092 Views Citations

Author(s)

Han Shen, Kerrie L. McDonald

Affiliation(s)

Cure for Life Neuro-Oncology Group, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South, Wales, Sydney, Australia.
Cure for Life Neuro-Oncology Group, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South, Wales, Sydney, Australia..

ABSTRACT

Glioblastoma is a highly malignant primary tumor of the central nervous system tumor with a poor survival rate. The treatment of glioblastoma is shifting from a purely cytotoxic approach to one that incorporates anti-angiogenic agents. Bevacizumab (Avastin; Roche) was approved in the United States for the treatment of recurrent glioblastoma in May 2009 and showed encouraging results. However, “rebound” tumor progression with accelerated clinical decline has been observed after cessation of bevacizumab therapy in patients with high-grade gliomas and there is no effective treatment for the recurrent glioblastoma after bevacizumab failure. This review summarizes the characteristics of glioblastoma as well as the possible mechanisms of recurrence after anti-angiogenic therapy. Furthermore, alterations of the key molecular pathways and glycometabolic remodeling in glioblastoma are also discussed within. A better understanding of the complexities underpinning the resistance to bevacizumab and the combination of targeting cancer metabolism and anti-VEGF therapy may ultimately result in new modes of treatment, which hopefully improve the overall survival for patients diagnosed with glioblastoma.

KEYWORDS

Glioblastoma; Bevacizumab; Relapse; Glycolysis

Share and Cite:

H. Shen and K. McDonald, "The Complexities of Resistance to Bevacizumab," Journal of Cancer Therapy, Vol. 3 No. 5, 2012, pp. 491-503. doi: 10.4236/jct.2012.35064.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies